US drug control policies: Federal spending on law enforcement versus treatment in public health outcomes

被引:4
|
作者
Shepard, E
Blackley, PR
机构
[1] Department of Economics, Le Moyne College
关键词
D O I
10.1177/002204260403400403
中图分类号
R194 [卫生标准、卫生检查、医药管理];
学科分类号
摘要
This paper evaluates the relationships among federal anti-drug law enforcement expenditures, education and treatment expenditures, and public health outcomes. The data include four types of spending: criminal justice system, interdiction and international intelligence, education in the community and workplace, and drug treatment These data were combined with mortality rates for drug abuse, a public health outcome. The empirical findings support the hypothesis that resources allocated to drug prevention and treatment have benefited the public health. Conversely, a 10% reduction in enforcement expenditures is associated with a long-run reduction of approximately 3,000 deaths per year.
引用
收藏
页码:771 / 785
页数:15
相关论文
共 31 条
  • [21] Incorporating a public health approach in drug law: Lessons from local expansion of treatment capacity and access under California's Proposition 36
    Klein, D
    Miller, RE
    Noble, A
    Speiglman, R
    MILBANK QUARTERLY, 2004, 82 (04): : 723 - 757
  • [22] US Food and Drug Administration, Centers for Disease Control and Prevention, and National Institutes of Health Co-Sponsored Public Workshop Summary-Development Considerations of Antimicrobial Drugs for the Treatment of Gonorrhea
    Hiruy, Hiwot
    Bala, Shukal
    Byrne, James M.
    Roche, Kerian Grande
    Jang, Seong H.
    Kim, Peter
    Nambiar, Sumathi
    Rubin, Dan
    Yasinskaya, Yuliya
    Bachmann, Laura H.
    Bernstein, Kyle
    Botgros, Radu
    Cammarata, Sue
    Chaves, Ricardo L.
    Deal, Carolyn D.
    Drusano, George L.
    Duffy, Erin M.
    Eakin, Ann E.
    Gelone, Steve
    Hiltke, Thomas
    Hook III, Edward W.
    Jerse, Ann E.
    Mcneil, Candice J.
    Newman, Lori
    O'Brien, Seamus
    Perry, Caroline
    Reno, Hilary E. L.
    Romaguera, Raul A.
    Sato, Junko
    Unemo, Magnus
    Wi, Teodora E. C.
    Workowski, Kimberly
    O'May, Graeme A.
    Shukla, Sunita J.
    Farley, John J.
    CLINICAL INFECTIOUS DISEASES, 2024,
  • [23] Reply from Authors re: James W. F. Catto. Health Care Spending, Social Policy, Public Health, and Life Expectancy: What Cancer Outcomes Can Tell Us Beyond Treatment Efficacy. Eur Urol 2011;60:16-8
    Bosetti, Cristina
    La Vecchia, Carlo
    Levi, Fabio
    EUROPEAN UROLOGY, 2011, 60 (01) : 19 - 20
  • [25] Modeling the Impact of Biomarker-Guided Versus ASCVD Risk-Guided Drug Treatment in US Adults With Stage 1 Hypertension: The National Health and Nutrition Examination Survey, 1999 to 2004
    Foti, Kathryn
    Wang, Dan
    Tang, Olive
    Daya, Natalie R.
    Commodore-Mensah, Yvonne
    Juraschek, Stephen P.
    Christenson, Robert H.
    Selvin, Elizabeth
    McEvoy, John W.
    HYPERTENSION, 2024, 81 (07) : 1599 - 1608
  • [26] COMPARISON OF HEALTH CARE RESOURCE USE AND COSTS IN PATIENTS WITH OPIOID PRESCRIPTION DRUG DEPENDENCE (OPD) TREATED WITH BUPRENORPHINE/NALOXONE AND PATIENTS WITHOUT PHARMACOLOGICAL TREATMENT: RETROSPECTIVE ANALYSIS OF US PUBLIC INSURANCE CLAIMS
    Khemiri, A.
    Clay, E.
    Kharitonova, E.
    Aballea, S.
    Zah, V
    Ruby, J.
    VALUE IN HEALTH, 2014, 17 (07) : A463 - A464
  • [27] Outcomes for Dostarlimab and Real-World Treatments in Post-platinum Patients With Advanced or Recurrent Endometrial Cancer: The GARNET Trial Versus a US Electronic Health Record-based Control Arm
    Goulden, Scott
    Shen, Qin
    Coleman, Robert L.
    Mathews, Cara
    Hunger, Matthias
    Pahwa, Ankit
    Schade, Rene
    JOURNAL OF HEALTH ECONOMICS AND OUTCOMES RESEARCH, 2023, 10 (02): : 53 - 61
  • [28] Gender differences in hypertension treatment, drug utilization patterns, and blood pressure control among US adults with hypertension: Data from the National Health and Nutrition Examination Survey 1999-2004
    Gu, Qiuping
    Burt, Vicki L.
    Paulose-Ram, Ryne
    Dillon, Charles F.
    AMERICAN JOURNAL OF HYPERTENSION, 2008, 21 (07) : 789 - 798
  • [29] PATIENT-REPORTED OUTCOMES, HEALTH CARE RESOURCES UTILIZATION, WORK PRODUCTIVITY AND THEIR ASSOCIATED COSTS IN PATIENTS WITH NEUROPATHIC PAIN: A CASE CONTROL COMPARISON OF TREATMENT WITH PREGABALIN VERSUS GABAPENTIN IN ROUTINE MEDICAL PRACTICE
    Perez, C.
    Navarro, A.
    Saldana, M. T.
    Masramon, X.
    Rejas, J.
    VALUE IN HEALTH, 2008, 11 (06) : A644 - A645
  • [30] Survival outcomes for dostarlimab and real-world (RW) treatment (tx) paradigms in post-platinum patients (pts) with advanced/recurrent (A/R) endometrial cancer (EC): The GARNET trial versus an external control arm from the Flatiron Health database.
    Coleman, Robert L.
    Shen, Qin
    Goulden, Scott
    Mathews, Cara Amanda
    Hunger, Matthias
    Pahwa, Ankit
    Schade, Rene
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)